MA39628B1 - Procédé de préparation d'amg 416 - Google Patents
Procédé de préparation d'amg 416Info
- Publication number
- MA39628B1 MA39628B1 MA39628A MA39628A MA39628B1 MA 39628 B1 MA39628 B1 MA 39628B1 MA 39628 A MA39628 A MA 39628A MA 39628 A MA39628 A MA 39628A MA 39628 B1 MA39628 B1 MA 39628B1
- Authority
- MA
- Morocco
- Prior art keywords
- amg
- preparing
- preparing amg
- shpt
- mbd
- Prior art date
Links
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 title abstract 3
- 229950006502 etelcalcetide Drugs 0.000 title abstract 3
- 108091022127 etelcalcetide hydrochloride Proteins 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 abstract 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 238000001631 haemodialysis Methods 0.000 abstract 1
- 230000000322 hemodialysis Effects 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
L'invention concerne un procédé de préparation d'amg 416, ou d'un sel pharmaceutiquement acceptable de celui-ci. Amg 416 est un peptide agoniste sélectif de synthèse à 8 acides aminés du récepteur sensible au calcium. Il a été développé pour servir de traitement intraveineux de l'hyperparathyroïdisme secondaire (shpt) chez les patients d'hémodialyse présentant des troubles minéraux et osseux de la maladie rénale chronique (ckd-mbd).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461974899P | 2014-04-03 | 2014-04-03 | |
EP15773570.5A EP3126373B1 (fr) | 2014-04-03 | 2015-04-03 | Procédé de préparation d'amg 416 |
PCT/US2015/024347 WO2015154031A1 (fr) | 2014-04-03 | 2015-04-03 | Procédé de préparation d'amg 416 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39628B1 true MA39628B1 (fr) | 2020-05-29 |
Family
ID=54241346
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39628A MA39628B1 (fr) | 2014-04-03 | 2015-04-03 | Procédé de préparation d'amg 416 |
MA052906A MA52906A (fr) | 2014-04-03 | 2015-04-03 | Procédé de préparation d'amg 416 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052906A MA52906A (fr) | 2014-04-03 | 2015-04-03 | Procédé de préparation d'amg 416 |
Country Status (27)
Country | Link |
---|---|
US (3) | US10407464B2 (fr) |
EP (3) | EP4219526A3 (fr) |
JP (1) | JP6710158B2 (fr) |
KR (1) | KR102397271B1 (fr) |
CN (1) | CN106795201A (fr) |
AU (1) | AU2015240527B2 (fr) |
BR (1) | BR112016022868A2 (fr) |
CA (1) | CA2944194C (fr) |
CL (1) | CL2016002513A1 (fr) |
CY (1) | CY1123100T1 (fr) |
DK (1) | DK3126373T3 (fr) |
EA (1) | EA032597B1 (fr) |
ES (2) | ES2786225T3 (fr) |
HR (1) | HRP20200527T1 (fr) |
HU (1) | HUE048489T2 (fr) |
IL (1) | IL248059B2 (fr) |
LT (1) | LT3126373T (fr) |
MA (2) | MA39628B1 (fr) |
ME (1) | ME03781B (fr) |
MX (1) | MX2016012965A (fr) |
PL (1) | PL3126373T3 (fr) |
PT (1) | PT3126373T (fr) |
RS (1) | RS60187B1 (fr) |
SG (1) | SG11201608176VA (fr) |
SI (1) | SI3126373T1 (fr) |
WO (1) | WO2015154031A1 (fr) |
ZA (1) | ZA201606844B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3246017B1 (fr) * | 2013-06-28 | 2021-03-24 | Amgen Inc. | Formulation liquide stable d'amg 416 hcl (etelcalcetide) |
EP4219526A3 (fr) | 2014-04-03 | 2023-08-30 | Amgen, Inc. | Procédé de préparation d'amg-24ib |
CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
CN106928320B (zh) * | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
EP3433267B1 (fr) * | 2016-03-23 | 2022-08-24 | Bachem Holding AG | Procédé de préparation de peptides de type glucagon |
US10858390B2 (en) | 2016-09-02 | 2020-12-08 | Cem Corporation | Use of excess carbodiimide for peptide synthesis at elevated temperatures |
CN108101959B (zh) * | 2016-11-24 | 2021-07-09 | 四川科伦药物研究院有限公司 | 一种制备高纯度多肽或其类似物的方法 |
CN106928171B (zh) * | 2017-05-03 | 2019-08-13 | 成都郑源生化科技有限公司 | Fmoc-Arg(Pbf)-OH的合成方法 |
TW201915009A (zh) * | 2017-10-03 | 2019-04-16 | 中化合成生技股份有限公司 | 合成依特卡肽(Etelcalcetide)或其鹽類之方法 |
CN110498835B (zh) * | 2018-05-17 | 2021-06-08 | 深圳翰宇药业股份有限公司 | 一种合成etelcalcetide的方法 |
CN109280078B (zh) * | 2018-10-30 | 2019-06-25 | 成都诺和晟泰生物科技有限公司 | 一种制备维拉卡肽的方法 |
CN112062811B (zh) * | 2019-06-10 | 2022-03-25 | 深圳翰宇药业股份有限公司 | 一种维拉卡肽的合成方法 |
US20220298206A1 (en) * | 2019-08-26 | 2022-09-22 | Auro Peptides Ltd | An improved process for the preparation of Etelcalcetide Hydrochloride |
EP3875466A1 (fr) * | 2020-03-05 | 2021-09-08 | Fresenius Kabi iPSUM S.r.l. | Procédé de synthèse de l'ételcalcétide |
TW202210498A (zh) | 2020-06-03 | 2022-03-16 | 日商中外製藥股份有限公司 | 高難度序列之有效率的胜肽縮合法 |
CN111925415A (zh) * | 2020-08-10 | 2020-11-13 | 海南中和药业股份有限公司 | 一种维拉卡肽杂质的制备方法 |
TWI792442B (zh) * | 2021-07-23 | 2023-02-11 | 建誼生技股份有限公司 | 依特卡肽鹽酸鹽之製造方法 |
CN114524860A (zh) * | 2021-12-29 | 2022-05-24 | 深圳翰宇药业股份有限公司 | 一种Etelcalcetide的合成方法及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
EP0339695A3 (fr) | 1988-04-29 | 1990-05-30 | Stichting Voor De Technische Wetenschappen | Procédé de préparation d'un conjugué antigénique ou immunogénique ainsi que l'utilisation de tels conjugués |
SE9603465D0 (sv) | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
NO311807B1 (no) | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
WO2009053315A1 (fr) | 2007-10-27 | 2009-04-30 | F. Hoffmann-La Roche Ag | Synthèse de peptides insulinotropes à l'aide de techniques hybrides utilisant une phase solide et une phase en solution |
CN101250172B (zh) | 2008-03-07 | 2012-05-02 | 上海瀚鸿化工科技有限公司 | 精氨酸双保护制备工艺 |
EP2427474A1 (fr) | 2009-05-06 | 2012-03-14 | Mallinckrodt LLC | Support solide pour la synthèse en phase solide basée sur fmoc d'acides peptidiques |
EP2459208B1 (fr) * | 2009-07-29 | 2016-09-28 | Kai Pharmaceuticals, Inc. | Agents thérapeutiques pour réduire les niveaux d' hormone parathyroïdienne |
EP2560491A1 (fr) * | 2010-04-21 | 2013-02-27 | Signature Therapeutics, Inc. | Agonistes opiacés périphériques et antagonistes opiacés périphériques |
US20140024592A1 (en) * | 2010-09-08 | 2014-01-23 | Howard Florey Institute Of Experimental Physiology And Medicine | Modified Relaxin Polypeptides |
WO2013042129A1 (fr) | 2011-09-23 | 2013-03-28 | Natco Pharma Limited | Procédé amélioré pour la préparation de bivalirudine |
EP3246017B1 (fr) | 2013-06-28 | 2021-03-24 | Amgen Inc. | Formulation liquide stable d'amg 416 hcl (etelcalcetide) |
EP4219526A3 (fr) | 2014-04-03 | 2023-08-30 | Amgen, Inc. | Procédé de préparation d'amg-24ib |
CN105504012A (zh) * | 2014-09-30 | 2016-04-20 | 深圳翰宇药业股份有限公司 | 一种多肽的制备方法 |
CN107434820A (zh) * | 2017-08-07 | 2017-12-05 | 南京工业大学 | 一种维拉卡肽的合成方法 |
-
2015
- 2015-04-03 EP EP23150870.6A patent/EP4219526A3/fr active Pending
- 2015-04-03 RS RS20200448A patent/RS60187B1/sr unknown
- 2015-04-03 JP JP2016560462A patent/JP6710158B2/ja active Active
- 2015-04-03 CN CN201580029560.2A patent/CN106795201A/zh active Pending
- 2015-04-03 EA EA201692001A patent/EA032597B1/ru not_active IP Right Cessation
- 2015-04-03 DK DK15773570.5T patent/DK3126373T3/da active
- 2015-04-03 SI SI201531173T patent/SI3126373T1/sl unknown
- 2015-04-03 LT LTEP15773570.5T patent/LT3126373T/lt unknown
- 2015-04-03 BR BR112016022868-5A patent/BR112016022868A2/pt active IP Right Grant
- 2015-04-03 EP EP15773570.5A patent/EP3126373B1/fr active Active
- 2015-04-03 EP EP20160369.3A patent/EP3708576B1/fr active Active
- 2015-04-03 IL IL248059A patent/IL248059B2/en unknown
- 2015-04-03 AU AU2015240527A patent/AU2015240527B2/en active Active
- 2015-04-03 HU HUE15773570A patent/HUE048489T2/hu unknown
- 2015-04-03 ES ES15773570T patent/ES2786225T3/es active Active
- 2015-04-03 ME MEP-2020-83A patent/ME03781B/fr unknown
- 2015-04-03 CA CA2944194A patent/CA2944194C/fr active Active
- 2015-04-03 US US15/300,209 patent/US10407464B2/en active Active
- 2015-04-03 ES ES20160369T patent/ES2943671T3/es active Active
- 2015-04-03 WO PCT/US2015/024347 patent/WO2015154031A1/fr active Application Filing
- 2015-04-03 KR KR1020167030590A patent/KR102397271B1/ko active IP Right Grant
- 2015-04-03 MA MA39628A patent/MA39628B1/fr unknown
- 2015-04-03 PT PT157735705T patent/PT3126373T/pt unknown
- 2015-04-03 MX MX2016012965A patent/MX2016012965A/es active IP Right Grant
- 2015-04-03 MA MA052906A patent/MA52906A/fr unknown
- 2015-04-03 SG SG11201608176VA patent/SG11201608176VA/en unknown
- 2015-04-03 PL PL15773570T patent/PL3126373T3/pl unknown
-
2016
- 2016-10-03 CL CL2016002513A patent/CL2016002513A1/es unknown
- 2016-10-05 ZA ZA2016/06844A patent/ZA201606844B/en unknown
-
2019
- 2019-08-05 US US16/532,344 patent/US11377474B2/en active Active
-
2020
- 2020-04-01 HR HRP20200527TT patent/HRP20200527T1/hr unknown
- 2020-04-29 CY CY20201100391T patent/CY1123100T1/el unknown
-
2022
- 2022-06-28 US US17/852,263 patent/US20230099078A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39628B1 (fr) | Procédé de préparation d'amg 416 | |
BR112017002001A2 (pt) | compostos e composição farmacêutica | |
EA201892207A1 (ru) | Индолкарбоксамидные соединения | |
MX2019012818A (es) | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. | |
MA43828A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
MA37888B1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
EA201790653A1 (ru) | Способ лечения болезни альцгеймера и других расстройств | |
EA201991078A1 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
BR112012016460A2 (pt) | diazóxido ou um sal farmaceuticamente aceitável deste e método para sua utilização no tratamento de uma doença desmielinizante autoimune do sistema nervoso central (cns), e composição farmacêutica. | |
PH12017500261A1 (en) | Substituted bicyclic compounds | |
MA40224B1 (fr) | Anticorps se liant aux protofibrilles ass améliorés | |
BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
MA39688B1 (fr) | Composés hétéroaryle pour le traitement de maladies ophtalmiques | |
TN2015000356A1 (en) | Bicyclic compounds | |
EA201790870A1 (ru) | Трициклические атропоизомерные соединения | |
MX2020013335A (es) | Metodos novedosos. | |
EA201691160A1 (ru) | Антагонисты s1p3 | |
EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
EA202190215A1 (ru) | Антагонисты рецептора p2x3 | |
PH12021550170A1 (en) | Pharmaceutical dosage form which can be adminitered orally and has modified release | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
PE20190382A1 (es) | Derivados etinilo | |
MA54530A (fr) | Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques | |
EA201892583A1 (ru) | Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора |